Characteristics

1) Cohort

2) Cohort

Entire

n = 54

LVEDP > 15

n = 28

LVEDP ≤ 15

n = 26

p-Value LVEDP > 15 vs < 15

Entire

n = 64

AS only n = 43

Age, y

66 ± 11.6

67 ± 11.8

64 ± 11.3

0.163

63 ± 13.8

67 ± 10.7

Men, n (%)

34 (63)

16 (57)

18 (69)

0.408

43 (68)

28 (65)

BMI

26 ± 3.2

26 ± 3.3

27 ± 3

1

27 ± 3.4

28 ± 3.5

EDD/BSA (mm/m2)

28.3 ± 4.4

29 ± 4.9

28 ± 3.9

0.451

28 ± 4.1

26 ± 3.5

ESD/BSA (mm/m2)

16.1 ± 4.4

16 ± 4.9

16 ± 3.9

0.844

15.1 ± 4.1

14 ± 3.5

E (cm/sec)

99 ± 28

97 ± 29.6

101 ± 26.6

0.553

101 ± 30.5

103 ± 29

E/A

1.14 ± 0.45

1.1 ± 0.4

1.2 ± 0.5

0.654

1.16 ± 0.54

1.12 ± 0.59

E-Deceleration time (msec)

245 ± 75

247 ± 79.5

242 ± 71.7

0.812

230 ± 66

241 ± 70.4

Main diseases

Aortic stenosis, n (%)

33 (61)

17 (61)

16 (62)

1

43 (67)

/

Regurgitation vitium, n (%)

18 (33)

11 (39)

7 (27)

0.396

21 (33)

/

Concomittant Diseases

Hyperlipidemia, n (%)

13 (24)

5 (18)

8 (31)

0.346

27 (42)

21 (49)

Hypertension, n (%)

26 (48)

17 (61)

9 (35)

0.064

34 (53)

26 (61)

Diabetes mellitus, n (%)

8 (15)

5 (18)

3 (12)

0.706

9 (14)

7 (16)

Coronary Artery Disease, n (%)

17 (32)

8 (29)

9 (35)

0.771

11 (17)

9 (21)

COPD, n (%)

6 (11)

4 (14)

2 (8)

0.670

3 (5)

2 (5)

Drug Therapy

ACEI/ARB, n (%)

42 (78)

23 (82)

19 (73)

0.521

50 (78)

31 (72)

ß-Blockers, n (%)

29 (54)

16 (57)

13 (50)

0.785

28 (44)

17 (40)